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Abstract: Background: Novel Psychoactive Substances (NPS) are a heterogeneous class of synthetic
molecules including synthetic cannabinoid receptor agonists (SCRAs). Psychosis is associated with
SCRAs use. There is limited knowledge regarding the structured assessment and psychometric
evaluation of clinical presentations, analytical toxicology and clinical management plans of patients
presenting with psychosis and SCRAs misuse. Methods: We gathered information regarding the
clinical presentations, toxicology and care plans of patients with psychosis and SCRAs misuse
admitted to inpatients services. Clinical presentations were assessed using the PANSS scale. Vital
signs data were collected using the National Early Warning Signs tool. Analytic chemistry data were
collected using urine drug screening tests for traditional psychoactive substances and NPS. Results:
We described the clinical presentation and management plan of four patients with psychosis and
misuse of SCRAs. Conclusion: The formulation of an informed clinical management plan requires a
structured assessment, identification of the index NPS, pharmacological interventions, increases in
nursing observations, changes to leave status and monitoring of the vital signs. The objective from
using these interventions is to maintain stable physical health whilst rapidly improving the altered
mental state.
Keywords: synthetic cannabinoids; SCRAs; NPS; novel psychoactive substances; NPS testing;
antipsychotics; mental health; physical health; nursing care; psychosis
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1. Introduction
Recent statistics in England have reported an increased number of hospital admissions with a
primary diagnosis of drug-related mental health/behavioural disorders and poisoning by illicit drugs,
respectively of 12 and 40% compared to statistics released in 2006/07 [1]. Over the last five years deaths
involving Novel Psychoactive Substances (NPS) have sadly increased, with a further 8% increase in
2016 [2]. NPS represent an emerging and concerning global phenomenon [3–5] mainly due to: (1) the
difficulties posed in the clinical management, of both mental and physical health; and (2) the absence
of a clear and formal/structured description of the clinical presentation of patients using NPS, with
obvious repercussions on clinical management.
NPS are a heterogeneous class of typically synthetic molecules including: synthetic cannabinoid
receptor agonists (SCRAs), synthetic cathinones, amphetamine-derivatives, psychedelic phenethylamines,
ketamine derivatives, novel tryptamines, synthetic opioids and sedatives (GABA-A/B agonists) [3,6,7].
Trends in illicit drug use over the last decade clearly show that adolescents and young adults give
preference to NPS instead of traditional psychoactive substances (TPS) (e.g., cannabis, cocaine, heroin,
amphetamines, LSD, ecstasy, ketamine, etc), because NPS are cheap and easily available either on the
street or from websites [6–8]. They are difficult to identify in blood or urine drug screening (UDS) [9].
Lifetime NPS consumption was reported by 8% of young individuals in 2015 [10] up from 5% in 2011 [6].
Young adults (aged 16 to 24) are around twice as likely to have used an NPS in their lifetime compared
to older adults (aged 16 to 59) [11]. It has recently been reported that the three psychiatric diagnoses
most frequently associated with NPS use are bipolar disorder (23.1%), personality disorders (11.8%), and
schizophrenia and related disorders (11.6%) [12].
In comparison to TPS users, poly NPS users are more likely to be young males [11], with daily use
of traditional cannabis, weekly or more use of ecstasy, recent LSD use, higher levels of poly drug use,
and a history of overdose on any drug in the past year [13]. Young adults attending nightlife events
in pubs and discos are also more prone to poly-substance use, mainly combining NPS with alcohol
and cocaine [14]. NPS users also tend to have a forensic history and a history of promiscuous sexual
activity (e.g., chem-sex) [13].
Few studies have attempted to provide a psychopathological description of the clinical
presentation of NPS users in acute settings. For example, in an observational cohort study enrolling
consecutive adult patients presenting to an Emergency Department (ED) in London, the most common
clinical features identified were seizures and agitation [15]. In a recent study looking into the impact
of NPS misuse on admissions to an acute psychiatric facility in London, increased levels of violence
in the group of NPS users were identified ([16]. Data collected in the Accident and Emergency
departments (A&Es) of ten European countries have shown that the association between NPS use and
the occurrence of psychosis varied considerably, depending on the type of drug used [17]. In particular,
psychotic symptoms were noted in 6.3% of a large sample (5529 consecutive cases), with psychosis
being more common amongst NPS users that had used tryptamines, methylenedioxypyrovalerone
(MDPV), methylphenidate, SCRAs and amphetamine-type compounds [17]. A mounting range of
evidence suggests that SCRAs can trigger the onset of acute psychosis in vulnerable individuals and/or
exacerbate psychotic episodes in those patients with a previous psychiatric history. The literature
reports a wide range of psychopathological issues such as paranoid thoughts, increases in aggressive
and combative behavior, together with confusion, agitation and suicidal thoughts [18]. It has
been suggested that SCRAs may have a higher psychosis-inducing potential compared to natural
cannabis [19] because of the lack of cannabidiol—a substance associated with the medicinal effects of
cannabis. For a review on existing studies and models of cannabis induced psychosis see a review
from Murray et al [20].
Professionals usually report feeling less confident about managing NPS compared to TPS users,
specifically because of the lack of clear guidance regarding the clinical management and the increased
risk of toxicity [10–18,21]. For example, with the ingestion of NPS with high serotonergic activity (e.g.:
psychedelic phenethylamines), misusers may present with hyperthermia, seizures, and hyponatraemia.
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Conversely, NPS with high dopaminergic activity (e.g., methylphenidate-like drugs such as some
synthetic cathinones) are highly addictive and associated with prolonged stimulation, insomnia,
agitation, and psychosis [22,23]. Furthermore, most SCRAs are at times associated with medical
emergencies such as hypertension, myocardial infarction, renal failure [24], elevated heart rate,
hyperglycaemia, nausea, vomiting, hypokalaemia, and seizures [18]. Moreover, in view of the increased
use of latest generation of sedatives or ultra-high potency fentanyl derivatives, the assessment of vital
parameters is of paramount importance when NPS users are presenting to an emergency or acute
facility [3–6].
The implementation of an appropriate and safe clinical management plan is commonly based
on patients’ accounts on which kind of NPS have been used. Acute mental health and emergency
services are not routinely equipped with urine drug screening tests (UDS) for NPS in order to identify
and provide an appropriate toxicological confirmation [15]. This causes considerable limitations
when offering a targeted treatment strategy that can address patients’ presentations and potentially
life-threatening intoxications [9,13,25].
At present, there is a dearth of detailed information relating to the clinical presentation of NPS
users in acute mental health settings, especially in terms of: (1) descriptions of behavioural and
psychopathological features using structured assessment and psychometric scales; (2) analytical
toxicology and identification of the index NPS used; and (3) appropriate and evidence-based clinical
management plans. This results in a range of difficulties in formulating targeted/individually tailored
treatment plans.
The aims of this case series are: (1) to offer a standardized description of NPS users’ clinical
presentations to provide clinicians with objective and measurable clinical pictures aimed at shaping
protocols and standard operating procedures when NPS use is suspected and/or detected; (2) to
provide best practice advice in the management of mental state alterations and medical complications,
with the goal of reducing the number of serious adverse outcomes associated with NPS use.
2. Materials and Methods
2.1. Study Design and Recruitment
Data on presentation and clinical management of 4 cases, selected amongst patients consecutively
admitted to two acute psychiatric wards from June 2017 to June 2018 at Highgate Mental Health
Centre—Camden & Islington NHS Foundation Trust—were retrospectively collected using a database.
Patients were aged 18 and 65 years and admitted because of presenting with psychotic illnesses and
with a history of NPS use before or during admission. Data were collected using a standardized
database to capture a range of information at baseline i.e., the time of the admission, and then during
and after NPS intake. The information collected revolved around: (1) the clinical presentation, with a
formal description of the psychotic symptoms; (2) the type of recreational drug(s) used; (3) the physical
health outcomes; (4) the levels of psychiatric inpatient observation and leave status.
The clinical presentation was identified with the help of clinical notes and corroborated by the
retrospective scoring of the Positive and Negative Syndrome Scale (PANSS), a multi-item questionnaire
widely used to quantify disease severity in schizophrenia and psychosis [26]. Monitoring data of
vital signs were collected using the National Early Warning Signs tool (NEWS) [27]. Data on the type
of substance used were collected using routine drug screening tests for traditional psychoactive
substances whilst a more thorough analysis (urine and/or oral fluids tests; Alere Laboratories
technologies) was carried out to identify the index drug(s) used by both NPS and TPS patients.
All subjects identified received medications included in the British National Formulary (BNF), such as
benzodiazepines (BZO) and antipsychotics (first and second generation), with the choice guided by
the clinical presentation and the drug testing results. Levels of nursing care, such as close or general
observations, were also recorded together with the possibility of leave in the hospital grounds , either
accompanied by staff (escorted) or alone (unescorted).
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2.2. Participants
2.2.1. Inclusion Criteria
Cases were selected amongst patients with recent or current histories of NPS use, aged 18–65 years,
presenting to acute services with a psychotic illness classified by the International Classification of
Diseases, Mental and Behavioral Disorders [28] as schizophrenia, schizotypal, delusional, and other
non-mood psychotic disorders (ICD-10 codes: F20-29), mood (affective) disorders (ICD-10 codes:
F30-39), and mental and behavioral disorders due to psychoactive substances (ICD-10 codes: F10-19).
2.2.2. Exclusion Criteria
Patients were excluded from the study if: (1) the psychotic symptoms were precipitated by an
organic cause; (2) they had moderate or severe learning disability; (3) they suffered from a medical or
neurological illness or (4) had an insufficient command of the English language.
2.3. Measures
2.3.1. Psychometric Measures
The Positive and Negative Symptoms Scale (PANSS) is a multi-item questionnaire widely used to
quantify disease severity in schizophrenia and to assess the severity of positive (or productive) and
negative (or deficit) symptoms of psychosis [26]. PANSS is easy to administer and is based on the
clinician’s interview with the patient; data are gathered looking at the patient's mental state over the
previous week, with the patient's family and/or his/her acquaintances being able to provide further
information. PANSS consists of 30 items and takes 45–50 min to be completed by the clinician.
The National Early Warning Score (NEWS; Royal College of Physicians, London, UK) [27] is a
standardized system for the assessment of acute illness in adults. It is based on six vital signs such as
respiratory rate, oxygen saturation, temperature, blood pressure, pulse/heart rate, and alertness. Each
parameter yields a score of between 0 and 3 so that when the scores for all the parameters are summed
a total NEWS score of between 0 and 18 is achieved. A score of 7 or greater indicates that a patient is
likely to be critically medically unwell.
2.3.2. Laboratory Measures
Standard urine drug screening tests were used to detect TPS such as heroin, cocaine, amphetamine,
THC, and methadone. For NPS, the Alere drug screening urine and oral fluids tests were used.
The urine tests provided a rapid screening of 30 synthetic cannabinoids at once whilst the oral
screening test was able to detect mephedrone.
3. Clinical Vignettes
3.1. Case 1—Mr A
28 years old Caucasian male, single and unemployed, living alone, with a positive forensic history
and a diagnosis of Paranoid Schizophrenia. The patient had a 4 years’ history of psychosis with
frequent relapses (5 admissions in 4 years). He was transferred to an acute treatment ward from
a psychiatric intensive care unit (PICU). At the time of the transfer the patient was stable and on
treatment with Risperdal Consta 37.5 mg fortnightly + Olanzapine 10 mg daily + Pregabalin 100 mg
daily. The PANSS score was 73/210 and his psychopathology was mainly characterized by positive
symptoms: delusional mood, persecutory and grandiose delusions and second and third person
auditory hallucinations. The UDS was initially negative but, one week after the transfer, Mr A’s mental
state deteriorated suddenly and he became very agitated and verbally and physically aggressive.
He presented with a bizarre and repetitive behaviour consisting of stopping and remaining immobile
for a few minutes and then running fast along the ward corridor. He also had second and third person
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auditory hallucinations, persecutory delusions and thought disorganization. He started to fear the
hospital ward’s electronic fire alarms. He believed that the fire alarms were cameras that were spying
on him and he was very preoccupied with specific members of the staff whom he believed were there
to kill him. The hallucinations also became very severe and he was responding to internal stimuli
constantly throughout the day. The total PANSS score was 109/210 and the UDS was positive for
SCRAs. We decided to increase Olanzapine to 20 mg, daily and to add Clonazepam 8 mg, daily to
manage the agitated behaviour and the psychotic symptoms. We also increased the level of monitoring
of his vital measures by completing the NEWS scores twice a day. NEWS scored 2 with increased
heart rate and fluctuating blood pressure. We considered a transfer to PICU but since the patient
was starting to respond well to the new treatment plan and the reason for the relapse was evident
(NPS intake), we decided to continue to treat the patient on the acute ward. Mr. A responded well to
the change/increase of medications, his symptoms improved in 24 h and within 7 days from the acute
intoxication the PANSS scores reduced to 74/210.
3.2. Case 2—Ms T
32 years old Caucasian woman, single and unemployed, living alone, with no forensic history
and a diagnosis of Schizoaffective Disorder and poly-substance misuse (mainly crack cocaine and
heroin). Ms T was stabilized on a combination of Aripiprazole 30 mg, daily + Lithium carbonate
800 mg, at night. The PANSS score was 95/210 and the UDS was negative for all illicit substances.
Four weeks later, the patient’s mental state deteriorated suddenly. She became physically and verbally
very aggressive with severe features of sexual disinhibition. The patient presented with delusional
mood and with complex grandiose and persecutory delusions such that she believed she was part
of a secret army and she had powers to kill people with her thoughts. She also believed she was
being chased by the Albanian mafia and had to fight for her life. The patient also became very
aggressive with members of staff and on four occasions it was necessary to call the emergency team to
provide extra sedation. The PANSS score was consistent with the deterioration of her mental state,
scoring 115/210 and the UDS tested positive for both SCRAs and THC. The clinical team felt that
the patient needed a more robust pharmacological treatment plan and therefore Haloperidol 10 mg
daily + Clonazepam 8 mg daily were added. The patient remained acutely unwell for more than
72 h. Ten days after the intoxication Ms T remained still irritable and agitated. The PANSS score was
115/210, 10 points higher than the baseline, and the UDS continued to test positive for SCRAs. NEWS
were increased to twice a day but the score was always within range (0 or 1) with tachycardia being
the only altered parameter. Meanwhile, other patients on the ward tested positive for SCRAs and it
was suspected that Ms T was bringing SCRAs to the ward. At that stage, leave was suspended and a
stricter search policy was enforced on the ward. The patient’s mental state improved further and ten
days later her urine tests were negative for SCRAs.
3.3. Case 3—Mr Y
20 years old Black-Caribbean male, single and unemployed, living with friends and with no
forensic history, was quickly re-admitted to a treatment ward following the sudden onset of bizarre
behaviour after an earlier discharge from another ward. The diagnosis was First Psychotic Episode
in the context of poly-substance misuse. On admission, Mr Y was on Haloperidol Decanoate 50 mg,
monthly + Haloperidol 10 mg, at night (on reducing regime). He appeared severely thought-disordered,
sexually disinhibited and aroused, approaching other patients for sex or suddenly becoming physically
aggressive by spitting on others. The PANSS score was 116/210 with prominent positive symptoms
(positive symptoms subscale 40/49). He presented as being severely disruptive, chaotic, and intrusive
into other patients’ care, attacking staff and other patients, urinating on the floor and spitting at other
people’s faces. Mr Y was therefore treated with Aripiprazole 9.75 mg three times a day + Clonazepam
6 mg daily in divided doses. Observation levels were increased to 2:1 arms’ length to reduce risks of
retaliation from others due to sexually inappropriate and aggressive behaviour. NEWS monitoring
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was increased to hourly to monitor any possible deterioration in physical health. UDS were positive
for benzodiazepines and SCRAs. The patient remained unwell. Observation levels were maintained at
2:1 arms’ length and NEWS monitoring decreased to TDS once physical outcomes remained stable for
12 h. After 72 h the clinical condition improved with a reduction of PANSS score to 98/210. Eventually,
because of the continued high risk of retaliation from others Mr. Y was transferred to a Psychiatric
Intensive Care Unit (PICU).
3.4. Case 4—Mr G
39 year old Asian British man, married and unemployed, living with his family and with a long
forensic history. Mr G had a long-standing history of Bipolar Disorder since the age of 28. He had a
history of numerous admissions, was non-compliant with his medications, and engaged poorly with
his community team. He presented with a long-term history of poly-substance misuse (e.g., alcohol,
cocaine, MDMA, cannabis, “legal highs”). He had previously been treated with a mood stabilizer
(Sodium Valproate); Zuclopenthixol and Risperidone Depot (both stopped due to sexual dysfunction);
Olanzapine and Quetiapine (both stopped due to poor response). At the time of his admission to
Highgate Mental Health Centre, he was administered Abilify Depot 400 mg, monthly with no or
little efficacy. He was transferred from another ward on Section 3 due to a manic relapse, with no
leave and a diagnosis of Bipolar Affective Disorder (BPAD, current episode manic). Mr. G had a
long history of violence towards staff and patients (he broke a nurse's nose and stabbed another
patient with a pen). At the time of the admission, he was very agitated, aggressive and intimidating,
banging his fist on the table and threatening staff with a glass bottle. He also showed bizarre behavior,
e.g., wearing sunglasses whilst indoors, holding pieces of paper with some incomprehensible notes
on Hitler, quantum physics and aliens. He was thought disordered with grandiose delusional beliefs
regarding him being the King of Egypt and able to cause a nuclear war. It proved very difficult to
verbally de-escalate him and he did not agree to change his medication regime as he believed that
he should be treated “only with love”. The PANSS score was 108/210. Abilify was withdrawn and
Zuclopenthixol started whilst he continued the rest of his medications. On admission, UDS was
negative for both NPS and TPS. A week later, UDS was positive for both benzodiazepines and SCRAs,
and NEWS was increased to TDS. Two weeks later, UDS continued to be positive to SCRAs, no changes
to his leave status were made, with garden leave being maintained. Three weeks after admission, UDS
was positive for benzodiazepines and THC and four weeks later the admission UDS was positive
for THC and SCRAs. After admission, his mental state remained unsettled with refractory manic
positive symptoms and a poor response to medication. The PANSS score was 123/210. Hence, his
leave was stopped and, a week later, his UDS became negative for all substances, SCRAs included.
His positive symptoms started to improve with a reduction of PANSS to 66/210. Over the following
four weeks Mr. G appeared well kempt and settled on the ward, with no grandiose delusions and no
further episodes of aggression. He showed a satisfactory response to Zuclopenthixol 300 mg, weekly
+ Sodium Valproate 1200 mg. UDS was negative for all substances and, therefore, Mr. G was safely
discharged to the community team.
4. Discussion
NPS misuse is a recent phenomenon and knowledge of its effects, either in the short or the
long term, on the population is relatively poor [3]. There is an increasing amount of knowledge
regarding the effect that NPS have on individuals with severe mental illness [12]. However, well
documented evidence of the negative impact are limited and most cases have not been corroborated
by analytic chemistry evidence of the NPS used [15]. Furthermore, there is a paucity of data to guide
the monitoring and management of patients with severe mental illness who take NPS, and then suffer
from acute psychopathology and physical ill-health [3].
To the best of our knowledge, our case series is the first and only attempt made at describing, with
the use of a specific psychometric scale (PANSS), the effects of acute intoxication with NPS (mainly
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SCRAs) identified through UDS in an acute hospital setting in patients suffering from severe psychotic
disorders. All four cases show how clinically significant the impact of SCRAs use was on their mental
states. The cases showed marked and sudden clinical deteriorations, with intense exacerbations of
positive symptoms, psychomotor agitation, sexual disinhibition, verbal/physical aggression, and poor
responses to medications. The latter phenomenon makes the clinical and risk management of these
patients more difficult, and it is therefore necessary to develop appropriate management plans to
minimize such risks.
In order to set up an appropriate and safe Informed Clinical Management Plan (ICMP) (Table 1),
the first step advised here is to establish, whenever possible, which NPS is responsible for the
intoxication due to their wide range of effects. We advocate, therefore, the use and further development
of reliable drug tests to identify the specific NPS types associated with particular clinical presentations.
Accurate testing for NPS would assist in establishing clear diagnoses, formulating ICMPs and
identifying the most effective treatments for intoxications with particular NPS.
Table 1. Description of the Camden & Islington—Informed Clinical Management Plan (ICMP).
Camden & Islington—Informed Clinical Management Plan (ICMP)
MENTAL STATE assessment
Using a psychometric scale (PANSS) Monitoring mental state
NPS detection
Using specific analytic toxicology to detect NPS
(UDS and/or oral swabs)
Monitoring access to substances and leaves
(reduced/suspended—escorted/unescorted)
MEDICATION & PHYSICAL HEALTH monitoring
Using benzodiazepines (BDZ) and/or second
generation antipsychotics (SGA) when possible
Monitoring physical health (NEWS)
Levels of nursing observations
The cases described here were all characterized by acute SCRA intoxications. The clinical
presentations were characterized by an acute onset of agitation and aggressive behavior; the symptoms
decreased in intensity and frequency in no less than 72 h. The management of acute intoxications was
by identifying the substances responsible for the sudden deteriorations, and by treating the symptoms
with benzodiazepines and antipsychotic medications. In addition vital parameters were monitored,
nursing observations were increased, and leave statuses were changed. These measures led to rapid
and successful resolutions of symptoms and reduced the need for transfer to more intensive care
settings. Furthermore, they promoted more rapid step-down and recovery in the community.
In general terms, pharmacological treatment remains the mainstay of treatment. However,
the novelty of the use of medications according to our protocol is that pharmacological interventions
are guided by NEWS and toxicology results. For example, haloperidol should be avoided in patients
that have used cathinones for the toxic effect on cardiac rhythm; and benzodiazepines should be
avoided in patient with a NEWS score of 3 because of low oxygen saturations levels.
In terms of pharmacological treatment, the use of BDZ has been recommended with or
without a second-generation antipsychotic (SGA) to reduce the risk of cardiac side effects [22,23].
Benzodiazepines remain the first line treatment, although their use needs to be weighed against the
risk of respiratory depression when given to subjects who have ingested alcohol and/or unknown
substances [6–18]. Amongst the SGAs, whilst aripiprazole is probably the safest antipsychotic to be
used in such scenarios because of its negligible effect on QTc, olanzapine has proven to be effective in
treating psychotic symptoms caused by NPS [29].
5. Limitations
We are aware that four cases are not representative of the multi-faceted spectrum of presentations
with NPS use/intoxication and observation of a wider sample size is necessary. However, we believe
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that this study is important in generating hypotheses that may lead to more comprehensive projects
such as case control studies.
Furthermore, although the four cases presented were objectively described by using the PANSS
to provide an objective measurement of the clinical observation, this was made retrospectively. We are
also aware that the patients described were intoxicated with SCRAs. No other NPS such as cathinones
or mephedrone were detected in our sample population. Therefore, our clinical description-albeit
exhaustive and comprehensive-is limited to a subgroup of NPS users using only SCRAs. Moreover
unfortunately, the UDS screening tests that were available were not able to identify with higher
specificity the type of SCRAs used.
It is worth noting how in terms of diagnostic categories our patients sample was not homogenous
as one of the four patients was presenting with bipolar disorder. This may be an additional confounding
factor; and, in a large enough sample, patients should be divided according to diagnoses.
Finally, a randomized controlled trial (RCT) to establish which ICMP is necessary to establish
which treatment plan is most effective in the management of individuals with a severe mental illness
intoxicated with NPS would be helpful.
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